Boulder Care Telehealth Platform
Telehealth addiction treatment for opioid and alcohol use disorder delivered via mobile app
Platform · Cloud SaaSCompany source
Company profile
About Boulder Care
Boulder Care is a telehealth addiction treatment provider that delivers comprehensive, evidence-based care for substance use disorder (SUD), including opioid use disorder (OUD) and alcohol use disorder (AUD). The company operates through a secure mobile application that connects patients with dedicated care teams comprising addiction medicine specialists, peer recovery specialists with lived experience, case managers, and care navigators. Boulder Care's model is grounded in harm reduction principles, offering non-punitive, patient-centered treatment without abstinence requirements or discharge for missed visits or returning to use. The platform provides medication-assisted treatment (MAT) including Suboxone prescriptions, comprehensive medical care for co-occurring mental health conditions such as anxiety, depression, PTSD, and insomnia, and recovery support services. Boulder Care accepts dozens of public and private health insurance plans and partners with health systems, health plans, employers, and referring providers to expand access to addiction treatment. The company's approach combines clinical expertise, proven research, and patient learnings to deliver coordinated outpatient care designed around individual patient goals. With industry-leading retention rates and patient satisfaction scores, Boulder Care aims to remove barriers, reduce stigma, and make high-quality addiction treatment accessible and convenient through telehealth delivery.
Company description Boulder Care official website
Primary marketMental Health & Digital Therapeutics
Commercial modelCommercial information available on request
Company presenceOfficial website
Work at Boulder Care?
Claim this listing Claim this profile to manage Company information and connect with the Health AI Central audience.
01 · Operating footprint
Where the Company operates
Company-profile context for clinical focus, customers, deployment, integration, milestones, and partnerships.
Clinical focus
- Alcohol Use Disorder (AUD)
- Anxiety
- Depression
- Insomnia
- Opioid Use Disorder (OUD)
- PTSD
- Substance Use Disorder (SUD)
Who it serves
- Employers
- FQHCs
- Health Plans
- Health Systems
- Individual patients
- Referring providers
Deployment & integration
Cloud Saas deployment with recorded integration context.
Geographic context
MarketsAlabama · Alaska · Arizona · Arkansas · California · Colorado · Connecticut · Delaware · Florida · Georgia · Hawaii · Idaho · Illinois · Indiana · Iowa · Kansas · Kentucky · Louisiana · Maine · Maryland · Massachusetts · Michigan · Minnesota · Mississippi · Missouri · Montana · Nebraska · Nevada · New Hampshire · New Jersey · New Mexico · New York · North Carolina · North Dakota · Ohio · Oklahoma · Oregon · Pennsylvania · Rhode Island · South Carolina · South Dakota · Tennessee · Texas · United States · Utah · Vermont · Virginia · Washington · West Virginia · Wisconsin · Wyoming
Company sourceOfficial website
Company milestones
Platform expansion
Completed multi-year study with OHSU demonstrating superior outcomes compared to treatment as usual; launched Recover Your Rights advocacy campaign for patient rights
Partnerships
Recorded partners
- Boulder Care Provider Group, P.A.
- FQHCs
- Harm reduction organizations
- Oregon Health & Science University (OHSU)
- Primary care physicians
02 · Flagship portfolio
Products, workflows, and platform capabilities
Selected source-backed Company products and the available commercial context.
03 · Research intelligence
Research Intelligence evidence
Publications, preprints, clinical validation, and regulatory records in Evidence Position order.
Evidence position
Publications, clinical validation, and regulatory records connected to this Company appear here.
Research
Publications & preprints
Retention in Telehealth-Delivered Buprenorphine Treatment for Opioid Use Disorder: Multistate Retrospective Cohort Study.Journal of medical Internet research · Aug 14, 2026
Retention in Telehealth-Delivered Buprenorphine Treatment for Opioid Use Disorder: A Multistate Retrospective Cohort Study.Journal of medical Internet research · Jul 8, 2026
State Proposed Strategies to Expand Access to Medications for Opioid Use Disorder.Health services research · Feb 1, 2026
How Did Medicaid's 1115 Substance Use Disorder Waivers Increase Medication Treatment for Opioid Use Disorder? Evidence From Eight Waiver States.The Milbank quarterly · Nov 1, 2025
"It's within your own power": shared decision-making to support transitions to buprenorphine.Addiction science & clinical practice · Mar 7, 2025
Buprenorphine discontinuation in telehealth-only treatment for opioid use disorder: A longitudinal cohort analysis.Journal of substance use and addiction treatment · Dec 1, 2024
Clinical validation
Clinical-trial records
Probiotic (LGG) for Veterans With PTSDNCT04150380 · Sponsor · COMPLETED
Right Tools, Right Time, Right Place: Telehealth for Opioid Use Disorder in Vulnerable SettingsNCT07169409 · Sponsor · RECRUITING
Evaluating the Efficacy of a Digital Platform to Deliver Comprehensive Treatment for Opioid Use DisorderNCT05529225 · Sponsor · COMPLETED
Acupressure and Stress ResilienceNCT01614444 · Sponsor · COMPLETED
Executive Dysfunction and Self-Harm Behavior: An Examination of Veterans With TBI, PTSD, or BothNCT01334463 · Sponsor · COMPLETED
Regulatory
Regulatory records
No linked records are currently available.
04 · Company-reported outcomes
Outcomes and case studies
Company-reported outcomes and customer stories are distinct from linked Research Intelligence evidence.
93% of patients meeting goals of reducing unwanted use
Patient goal achievement
74% of patients rate recovery progress as good to excellent
Patient satisfaction
86 Net Promoter Score (NPS)
Over 2x the industry average
94% retention at 24 weeks
OHSU study cohort
90% retention at 48 weeks
OHSU study cohort
63% of patients work with Boulder for 6+ months
Compared to 29% industry average
2 days average time to get into care
Access speed
62% improvement in risk of drop out
Compared to treatment as usual in OHSU study
Oregon Health & Science University (OHSU)
Multi-year study comparing Boulder's telehealth model to OHSU's outpatient program for addiction treatment
94% retention at 24 weeks, 90% retention at 48 weeks, and 62% improvement in risk of drop out compared to treatment as usual cohort
05 · Leadership
Leadership team
Leadership profiles and professional links from the current Company record.
No active leadership profiles are currently listed.
06 · Company updates
Updates from Boulder Care
Recent articles published on Boulder Care's official website.
07 · HAIC coverage
Coverage and analysis
Health AI Central reporting that mentions this Company.
No HAIC coverage is currently linked to this Company.
08 · Official presence
Company sources and channels
Curated official destinations from the active Company record.
09 · Market pathway
Additional Companies in this Market
Other active Companies in the same market, selected alphabetically from the HAIC directory.
Market context
Mental Health & Digital Therapeutics
Companies providing AI-powered mental health support, therapy platforms, mental wellness tracking, psychiatric care, digital therapeutics for mental health conditions, or AI-driven mental health screening and monitoring. Includes XR-based therapy, AI mental health screening infrastructure, and platforms supporting behavioral health for individuals and health systems.
Explore the full market directory or compare this Company with additional active profiles.
View all Companies in this market
10 · Pro research
Coming soon
Expanded Company research is in development.
Health AI Central Pro · Coming Soon
Deeper Company research is coming soon.
Pro Research will introduce expanded technical context, linked evidence analysis, and comparative Company research.
Linked research, clinical, and regulatory source pathways.
Expanded product, deployment, integration, and partnership research.
Record-level provenance and review context.